Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis
JAMA · 09.05.2023 · 329 (18) · 1558
DOI: 10.1001/jama.2023.4902 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 09.05.2023. Verfasst von Alexandre Louvet und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Lille, CHU de Lille, Service des maladies de l'appareil digestif, Hôpital Huriez, INFINITE-U1286, Lille, France. Hauptthemen laut MEDLINE: Amoxicillin-Potassium Clavulanate Combination, Anti-Bacterial Agents, Antibiotic Prophylaxis, Hepatitis, Alcoholic. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The benefits of prophylactic antibiotics for hospitalized patients with severe alcohol-related hepatitis are unclear.
Objective
To determine the efficacy of amoxicillin-clavulanate, compared with placebo, on mortality in patients hospitalized with severe alcohol-related hepatitis and treated with prednisolone. Design, Setting, and Participants Multicenter, randomized, double-blind clinical trial among patients with biopsy-proven severe alcohol-related hepatitis (Maddrey function score ≥32 and Model for End-stage Liver Disease [MELD] score ≥21) from June 13, 2015, to May 24, 2019, in 25 centers in France and Belgium. All patients were followed up for 180 days. Final follow-up occurred on November 19, 2019.
Intervention
Patients were randomly assigned (1:1 allocation) to receive prednisolone combined with amoxicillin-clavulanate (n = 145) or prednisolone combined with placebo (n = 147). Main Outcome and Measures The primary outcome was all-cause mortality at 60 days. Secondary outcomes were all-cause mortality at 90 and 180 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants with a MELD score less than 17 at 60 days; and proportion of patients with a Lille score less than 0.45 at 7 days.
Results
Among 292 randomized patients (mean age, 52.8 [SD, 9.2] years; 80 [27.4%] women) 284 (97%) were analyzed. There was no significant difference in 60-day mortality between participants randomized to amoxicillin-clavulanate and those randomized to placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [ P = .33]; between-group difference, −4.7% [95% CI, −14.0% to 4.7%]; hazard ratio, 0.77 [95% CI, 0.45-1.31]). Infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, −11.8% [95% CI, −23.0% to −0.7%]; subhazard ratio, 0.62; [95% CI, 0.41-0.91]; P = .02). There were no significant differences in any of the remaining 3 secondary outcomes. The most common serious adverse events were related to liver failure (25 in the amoxicillin-clavulanate group and 20 in the placebo group), infections (23 in the amoxicillin-clavulanate group and 46 in the placebo group), and gastrointestinal disorders (15 in the amoxicillin-clavulanate group and 21 in the placebo group). Conclusion and Relevance In patients hospitalized with severe alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone did not improve 2-month survival compared with prednisolone alone. These results do not support prophylactic antibiotics to improve survival in patients hospitalized with severe alcohol-related hepatitis. Trial Registration ClinicalTrials.gov Identifier: NCT02281929
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Lille, CHU de Lille, Service des maladies de l'appareil digestif, Hôpital Huriez, INFINITE-U1286, Lille, France.
- Unité de biostatistiques, CHU de Lille, Lille, France.
- Service d'hépato-gastroentérologie, CHU de Caen, Caen, France.
- Service d'hépatologie, Hôpital Jean-Minjoz, CHU de Besançon, Besançon, France.
- Service d'hépato-gastroentérologie, CHU d'Angers, Angers, France.
- Service d'hépatologie, CHU de Toulouse, Toulouse, France.
Zitieren
APA
Louvet, A., Labreuche, J., Dao, T., Thévenot, T., Oberti, F., Bureau, C., Paupard, T., Nguyen-Khac, E., Minello, A., Bernard-Chabert, B., Anty, R., Wartel, F., Carbonell, N., Pageaux, G. P., Hilleret, M. N., Moirand, R., Nahon, P., Potey, C., Duhamel, A., & Mathurin, P. (2023). Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis. JAMA, 329(18), 1558. https://doi.org/10.1001/jama.2023.4902
Vancouver
Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, et al. Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis. JAMA. 2023;329(18):1558. doi:10.1001/jama.2023.4902
BibTeX
@article{Louvet2023,
author = {Louvet, Alexandre and Labreuche, Julien and Dao, Thong and Thévenot, Thierry and Oberti, Frédéric and Bureau, Christophe and Paupard, Thierry and Nguyen-Khac, Eric and Minello, Anne and Bernard-Chabert, Brigitte and Anty, Rodolphe and Wartel, Faustine and Carbonell, Nicolas and Pageaux, Georges-Philippe and Hilleret, Marie-Noelle and Moirand, Romain and Nahon, Pierre and Potey, Camille and Duhamel, Alain and Mathurin, Philippe},
title = {Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis},
journal = {JAMA},
year = {2023},
volume = {329},
number = {18},
pages = {1558},
doi = {10.1001/jama.2023.4902}
}
EUVIMED